Dilated cardiomyopathies and non-compaction cardiomyopathy

Hänselmann, Anja; Veltmann, Christian; Bauersachs, Johann; Berliner, Dominik

doi:10.1007/s00059-020-04903-5

Cited by 27 publications

(20 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The pathway pathways involving overexpressed mRNA not only show cellular metabolic pathways such as citric acid cycle (TCA cycle) and oxidative phosphorylation but also are related to atherosclerosis, viral infection, and even a variety of neurodegenerative diseases (Parkinson's disease, Huntington's disease, Alzheimer's disease, etc.). The diversity of pathways in which it is involved corresponds to its various pathogenic factors such as cardiotoxic compounds, metabolism, rheumatological and endocrine diseases, and cellular infiltration and viral infection [16]. Due to multiple heterogeneous etiologies, dilated cardiomyopathy is an "umbrella" term that describes the final common pathway of different pathogenic processes and gene-environment interactions [17].…”

Section: Discussionmentioning

confidence: 99%

“…In most cases, dilated cardiomyopathy treatment refers to heart failure treatment based on medical treatment with angiotensin-converting enzyme inhibitors (angiotensin receptor blockers or angiotensin receptor/neprilysin inhibitors, if applicable), beta-blockers, and mineralocorticoid receptor antagonists according to current guidelines for heart failure [16]. Different from the previous ideas of symptomatic treatment with drugs to delay disease progression, this study selects the corresponding drugs through multiple Journal of Nanomaterials pharmacogenomics databases based on the new thinking of targeted therapy for specific disease mechanisms to reverse the disease process, targeting the 12 mRNAs overexpressed in the network and their encoded proteins, and the mechanistic analysis of the downregulation of mRNA expression and inhibition of proteins by these drugs in the future will further reveal the common pathways of their effects, which can be used as the starting point for subsequent studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bioinformatics-Based Identification of lncRNA-miRNA-mRNA Network in Dilated Cardiomyopathy and Drug Prediction

Liu

Cai

Tang

et al. 2021

Journal of Nanomaterials

View full text Add to dashboard Cite

Background. Dilated cardiomyopathy (DCM) is a cardiovascular disease of unknown etiology with progressive aggravation. More and more studies have shown that long noncoding RNAs (lncRNAs) play an essential role in dilated cardiomyopathy formation and development. The mechanism of action of competitive endogenous RNA (ceRNA) networks formed based on the principle that lncRNAs affect mRNAs’ expression level by competitively binding microRNAs (miRNAs) in dilated cardiomyopathy has rarely been reported. Objective. This study is aimed at constructing a lncRNA-miRNA-mRNA ceRNA network by bioinformatics analysis methods, discovering, and validating potential biomarkers of DCM in the ceRNA network and determining possible therapeutic targets from them for drug prediction. Methods. A lncRNA dataset and a mRNA microarray dataset were downloaded from the Gene Expression Omnibus Database (GEO). Gene expression was compared between blood samples from patients with dilated cardiomyopathy and blood samples from normal subjects to identify differential expression of lncRNAs and mRNAs. The lncRNA-miRNA-mRNA network was constructed using bioinformatics tools, and functional and pathway enrichment analysis and protein-protein interactions were performed. The mRNAs in the network and the proteins they encode are then used as targets for predicting drugs. Besides, the expression of lncRNAs in the ceRNA network was validated by real-time quantitative PCR (qRT-PCR) experiments in vitro. Results. The differentially expressed lncRNA-miRNA-mRNA ceRNA network in dilated cardiomyopathy was successfully established. Two differentially overexpressed key lncRNAs were found from the network: AC093817 and AC091062, and qRT-PCR experiments further validated the overexpression of AC093817 and AC091062. The mRNAs in the network and the proteins encoded by the mRNAs were used for drug prediction to get related drugs. Conclusion. This study supports a possible mechanism and drug development of dilated cardiomyopathy, AC093817 and AC091062 being potential biomarkers of dilated cardiomyopathy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Bioinformatics-Based Identification of lncRNA-miRNA-mRNA Network in Dilated Cardiomyopathy and Drug Prediction

Liu

Cai

Tang

et al. 2021

Journal of Nanomaterials

View full text Add to dashboard Cite

show abstract

“…Thus, BBR could improve EAM by differentially regulating the activities of p-STAT1, p-STAT3 and p-STAT4, which further inhibited the differentiation of Th17 and Th1 cells ( Liu et al, 2016 ). Dilated cardiomyopathy is the most common form of cardiomyopathy induced by a variety of causes, ranging from myocarditis to alcohol and other toxins such as drugs, cardiotoxins and chemotherapeutic agents, to rheumatic, endocrine and metabolic diseases, all of which can lead to reduced left ventricular systolic function and left ventricular or biventricular dilatation ( Hänselmann et al, 2020 ). The anthracycline anticancer drug doxorubicin (DOX) is an effective and commonly used chemotherapeutic agent for the treatment of malignancies, and its main side effect is cardiotoxicity.…”

Section: Myocarditis and Cardiomyopathymentioning

confidence: 99%

A New Therapeutic Candidate for Cardiovascular Diseases: Berberine

Cai

Xin

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) are the leading cause of death in the world. However, due to the limited effectiveness and potential adverse effects of current treatments, the long-term prognosis of CVD patients is still discouraging. In recent years, several studies have found that berberine (BBR) has broad application prospects in the prevention and treatment of CVD. Due to its effectiveness and safety for gastroenteritis and diarrhea caused by bacterial infections, BBR has been widely used in China and other Asian countries since the middle of the last century. The development of pharmacology also provides evidence for the multi-targets of BBR in treating CVD. Researches on CVD, such as arrhythmia, atherosclerosis, dyslipidemia, hypertension, ischemic heart disease, myocarditis and cardiomyopathy, heart failure, etc., revealed the cardiovascular protective mechanisms of BBR. This review systematically summarizes the pharmacological research progress of BBR in the treatment of CVD in recent years, confirming that BBR is a promising therapeutic option for CVD.

show abstract

“…In 30–50% of cases of DCM in humans, a genetic cause can be found. 13 To date, more than 30 genes are known to cause DCM in humans. 14 Most affected genes code for ion channels, sarcomeres, Z-discs, nuclear proteins and desmosomes but 20% are found in the gene that encodes for titin.…”

Section: Dilated Cardiomyopathymentioning

confidence: 99%

The Feline Cardiomyopathies: 3. Cardiomyopathies other than HCM

Kittleson

Côté

2021

Journal of Feline Medicine and Surgery

View full text Add to dashboard Cite

Practical relevance: Although feline hypertrophic cardiomyopathy (HCM) occurs more commonly, dilated cardiomyopathy (DCM), restrictive cardiomyopathy (RCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), left ventricular noncompaction (LVNC) and cardiomyopathy – nonspecific phenotype (NCM; formerly unclassified cardiomyopathy) are all recognized in domestic cats. Patient group: Any adult domestic cat, of either sex and of any breed, can be affected. Diagnostics: The non-HCM cardiomyopathies are rarely suspected in subclinically affected cats, so most are first identified when a cat presents with signs of heart failure or systemic thromboembolic disease. The definitive clinical confirmatory test for these other feline cardiomyopathies is echocardiography. Key findings: ‘Cardiomyopathy – nonspecific phenotype’ is a catch-all term that groups hearts with myocardial changes that either do not meet the criteria for any one type of cardiomyopathy (HCM, RCM, DCM, ARVC, LVNC) or meet the echocardiography criteria for more than one type. RCM is characterized by diastolic dysfunction due to fibrosis that results in a restrictive transmitral flow pattern on Doppler echocardiography and usually marked left or biatrial enlargement. DCM is characterized by decreased myocardial contractility and is rare in cats. When it occurs, it is seldom due to taurine deficiency. However, since taurine-deficient DCM is usually reversible, a diet history should be obtained, whole blood and plasma taurine levels should be measured and taurine should be supplemented in the diet if the diet is not commercially manufactured. ARVC should be suspected in adult cats with severe right heart enlargement and right heart failure (ascites and/or pleural effusion), especially if arrhythmia is present. Feline LVNC is rare; its significance continues to be explored. Treatment of the consequences of these cardiomyopathies (management of heart failure, thromboprophylaxis, treatment of systemic arterial thromboembolism) is the same as for HCM. Conclusions: While these other cardiomyopathies are less prevalent than HCM in cats, their clinical and radiographic presentation is often indistinguishable from HCM. Echocardiography is usually the only ante-mortem method to determine which type of cardiomyopathy is present. However, since treatment and prognosis are often similar for the feline cardiomyopathies, distinguishing among the cardiomyopathies is often not essential for determining appropriate therapy. Areas of uncertainty: The feline cardiomyopathies do not always fit into one distinct category. Interrelationships among cardiomyopathies in cats may exist and understanding these relationships in the future might provide critical insights regarding treatment and prognosis.

show abstract

Dilated cardiomyopathies and non-compaction cardiomyopathy

Cited by 27 publications

References 61 publications

Bioinformatics-Based Identification of lncRNA-miRNA-mRNA Network in Dilated Cardiomyopathy and Drug Prediction

Bioinformatics-Based Identification of lncRNA-miRNA-mRNA Network in Dilated Cardiomyopathy and Drug Prediction

A New Therapeutic Candidate for Cardiovascular Diseases: Berberine

The Feline Cardiomyopathies: 3. Cardiomyopathies other than HCM

Contact Info

Product

Resources

About